Información del producto
DY 268 is a coumarin derivative that binds to the prostate-specific membrane antigen (PSMA) and is being developed as a treatment for prostate cancer. This compound has been shown to inhibit the transport rate of PSMA, which prevents it from binding to the receptor. DY 268 has also been shown to be an effective adjuvant therapy for chronic inflammatory diseases such as rheumatoid arthritis. DY 268 was activated in human liver cells, and its growth factor activity was found to be localized in proximal tubules.